Effects of topical steroids in patients with eosinophilic esophagitis (EoE).

No registrations found.

Ethical review Positive opinion **Status** Recruiting

Health condition type -

Study type Interventional

Summary

ID

NL-OMON25172

Source

Nationaal Trial Register

Health condition

Eosinophilic esophagitis, etiology, pathophysiology, epithelial barrier function, permeability, steroids, treatment, therapy.

Eosinofiele oesofagitis, etiologie, pathofysiologie, epitheliale barrierefunctie, permeabiliteit, steroiden, behandeling, therapie.

Sponsors and support

Primary sponsor: Academic Medical Center, Amsterdam, The Netherlands

Source(s) of monetary or material Support: Academic Medical Center, Amsterdam, The

Netherlands

Intervention

Outcome measures

Primary outcome

Tissue impedance, intercellular spaces, and mucosal permeability to small molecules before and after treatment with 500 μ g fluticasone propionate twice daily for 8 weeks.

Secondary outcome

Numbers of esophageal intraepithelial eosinophils and mast cells before and after treatment with 500 μ g fluticasone propionate twice daily for 8 weeks.

Study description

Background summary

An impaired epithelial barrier function is suggested to play a role in the pathophysiology of EoE. Standard treatment is with topical corticosteroids. EoE patients will be treated with swallowed fluticasone aerosole for 8 weeks. Endoscopy will be performed at baseline and after steroid therapy, to determine the effect on several epithelial barrier function parameters and eosinophilia.

Study objective

An impaired epithelial barrier function is suggested to play a role in the pathophysiology of EoE. Standard treatment with topical corticosteroids results in a reduction of symptoms and esophageal eosinophilia. We hypothesize that by treating EoE patients with swallowed fluticasone propionate, the esophageal epithelial barrier function could be restored. The effect of topical corticosteroid therapy on the epithelial barrier function has never been investigated before.

Study design

At baseline and after 8 weeks of treatment with fluticasone.

Intervention

EoE patients will be treated with fluticasone 500 mcg bd for 8 weeks.

Contacts

Public

Motility Center, room C2-231

Academic Medical Center

PO Box 22660
B.D. Rhijn, van
Amsterdam 1100 DD
The Netherlands

+31 (0)20 5665584

Scientific

Motility Center, room C2-231

Academic Medical Center

PO Box 22660
B.D. Rhijn, van
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5665584

Eligibility criteria

Inclusion criteria

- 1. Previous diagnosis of EoE confirmed by histopathology e.g. presence of >15 eosinophilic granulocytes per high power field (hpf) in mid-esophageal biopsies before the start of any therapy;
- 2. Written informed consent;
- 3. Age 18 75 years.

Exclusion criteria

- 1. Inability to stop PPI, H2-receptor antagonist or prokinetic drug for 8 weeks;
- 2. Use of systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the two month period preceding the study;
- 3. Use of anticoagulants;
- 4. Use of NSAIDs;
- 5. History of Barrett's esophagus;
- 6. History of upper GI tract surgery;
- 7. ASA class IV or V.

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: N/A: single arm study

Masking: Open (masking not used)

Control: N/A, unknown

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 29-02-2012

Enrollment: 12

Type: Anticipated

Ethics review

Positive opinion

Date: 18-06-2012

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 37559

Bron: ToetsingOnline

Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL3355 NTR-old NTR3487

CCMO NL39184.018.11

ISRCTN wordt niet meer aangevraagd.

OMON NL-OMON37559

Study results

Summary results

N/A